Symray Biopharma

Symray Biopharma is a Shanghai-based private biotech focused on discovery and early development of innovative antibody therapeutics. The company operates integrated antibody discovery, antibody characterization, and drug validation platforms and applies them to monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, fusion proteins, and selected CAR-T programs. Its disclosed pipeline is concentrated in preclinical oncology, inflammation, autoimmune, cardiovascular/thrombosis, metabolic, ophthalmology, and rare disease programs. Symray also appears to pursue partnered and co-development deals alongside internal pipeline creation, positioning itself as an antibody innovation and translational R&D company rather than a commercial-stage biopharma.